MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-09-2023
Aravive Operating Income 2011-2026 | ARAV
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Aravive
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -70.8 M | -40.6 M | -30.8 M | -21.8 M | -75.4 M | -84.5 M | -96.3 M | -82.5 M | -46.1 M | -19.3 M | -12.9 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -12.9 M | -96.3 M | -52.8 M |
Quarterly Operating Income Aravive
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.91 M | -12.6 M | -17.9 M | - | -16.5 M | -19.4 M | -15 M | - | -11.6 M | -7.41 M | -8.01 M | - | -10.7 M | -5.72 M | -10.3 M | - | -7 M | -3.87 M | -5.74 M | - | -6.22 M | -9.44 M | -8.52 M | 31.1 M | -49.7 M | -36.2 M | -29.7 M | -22.5 M | -27.4 M | -22.3 M | -24.1 M | -20.2 M | -20.5 M | -19.5 M | -22.3 M | -15.9 M | -14.1 M | -8.5 M | -7.58 M | -5.86 M | -5.26 M | -3.98 M | -4.18 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 31.1 M | -49.7 M | -13.5 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M |  USA |
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Amarin Corporation plc
AMRN
|
-67.6 M | $ 15.02 | - | $ 6.12 B |  Irlanda |
 |
Adagene
ADAG
|
-36 M | $ 2.98 | - | $ 168 M |  China |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioNTech SE
BNTX
|
15.3 B | $ 108.93 | - | $ 27.2 B | Germany |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 9.24 | - | $ 1.47 B | Britain |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Athira Pharma
ATHA
|
-101 M | - | - | $ 269 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-209 M | - | - | $ 1.01 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 4.34 | - | $ 9.44 B |  Israel |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 224.05 | -0.06 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-624 M | - | -6.81 % | $ 3.04 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-568 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aridis Pharmaceuticals
ARDS
|
-30 M | - | 17.91 % | $ 11.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Athersys
ATHX
|
-87.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Baudax Bio
BXRX
|
-56.8 M | - | 0.59 % | $ 63 K | USA |
 |
Cabaletta Bio
CABA
|
-74.7 M | $ 2.6 | - | $ 3.04 M | USA |
 |
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | USA |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.43 | - | $ 365 M | Britain |
 |
Catalyst Pharmaceuticals
CPRX
|
195 M | $ 24.27 | - | $ 2.87 B | USA |
 |
Amneal Pharmaceuticals
AMRX
|
249 M | $ 14.76 | - | $ 4.56 B | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
|
Champions Oncology
CSBR
|
4.55 M | $ 6.12 | -6.56 % | $ 83.6 M | USA |